How tumour cell identity is established? by Sánchez García, Isidro
How tumour cell identity is established? 
Isidro Sánchez-García 
 
The enormous increase in our understanding of the biology of tumour cells in 
the last four decades did not have a proportional impact in our capacity of 
controlling the development of the disease. We do not know how to stop a pre-
cancer cell developing into a cancer yet, mainly due to the fact that the early 
events that determine the fate and lineage commitment of cancerinitiated cells 
remain largely unknown. The consequences of this lack of knowledge about the 
initiation of cancer is well illustrated by women carrying a BRCA1 or BRCA2 
mutation who choose to undergo prophylactic bilateral total mastectomy for 
reducing the risk of breast cancer. Clearly, the most critical point of cancer 
development is the transition from a normal target cell to a cancer cell. 
However, the mechanisms establishing tumour cellular identity, which play an 
essential role in allowing cancers to arise, have received little attention. From 
this perspective, at least three are the key questions for understanding the 
cancer initiation process. What are the leads instructing a target cell carrying an 
oncogene to switch from a normal to a cancerous identity fate? What is the 
molecular nature of the cancer cell switch? When, during normal cell 
development, does this switch take place? This last question is critical because, 
to find the players of the normal/cancer switch mechanism, one has to know 
when/where to look. The mechanisms initiating cancer must integrate 
developmental cues (different between cancer types) with the universal 
requirements for the creation of a tumour mass. Although it is generally believed 
that the decision to become a cancer cell must be made once the normal cell 
has adopted a cell identity fate compromise in the majority of cancers, recent 
data suggest that this timing of cancer initiation is not a universal feature shared 
by many oncogenes. Actually, several recent papers have found that 
oncogenes contribute to cancer development not only by inducing proliferation, 
but mainly via developmental reprogramming of the epigenome of the tumour 
target cell. Indeed, using stemcell restricted transgenic expression systems, it 
has been shown that the expression of the oncogene in the reprogramming-
prone stem/progenitor cells is capable of programming the development of all 
the cells that compose the tumour mass. Overall, these results not only highlight 
a previously unrecognized role for oncogenes in cancer, but also provide 
evidence for a previously unmodeled process for tumourigenesis in which the 
programming of the malignant tumour cell identity has already taken place at 
the stem cell stage,thus uncovering a new role for oncogenes in the timing of 
cancer initiation. In this context, mutations that activate oncogenes would have 
a driving role in the reprogramming process, but may act as passenger 
mutations (or have a secondary, different role) thereafter. These findings open 
new questions. First, is the decision to initiate cancer made at one time point 
during the differentiation process, or are a series of consecutive decisions 
required to switch to a cancer-cell fate? and, are all these decisions cell-
autonomous? What is the nature of the (epi)genetic pathway downstream from 
the cancer-specific initiation gene defect(s)? If we learn how to stop cancer 
development by manipulating the cancer-initiation programme then, someday, 
understanding the initiation of cancer will also be useful for cancer therapy. It is 
our task not only to address these and other questions, but to determine their 
relative importance for each stage and type of cancer.  
Furthermore, the biology of cancer cell commitment is relevant not only to 
understand stem cell properties of cancers and in developing cancer treatment 
strategies but also to regenerative medicine, as it is clearly imperative that 
regenerative medicine gains full control over reprogrammed cell fates. This 
issue of Seminars in Cancer Biology presents a series of chapters illustrating 
current knowledge, unusual perspectives and novel interpretations on how 
reprogrammed tumour cell fates influence the carcinogenic sequence. The 
reader can easily verify thatthe views expressed in this issue of Seminars in 
Cancer Biology, including those ofthe Guest-Editor, are by no means 
homogeneous. In fact,they offer a representative cross section of different 
research orientations currently present in the field. I feel that a better definition 
of the specific subjects related to the “tumour stem cell reprogramming” would 
help in integrating these different views and in coordinating research efforts 
towards the common of understanding how tumour cell identity is established. 
The coming years will show whether this optimism is well founded, or whether 
the immense complexity of this disease will continue to confound our best 
endeavours to tackle cancer. 
